Current options for the treatment of cryopyrin-associated periodic syndromes

Bibliography

• Hoffman HM, Wanderer AA, Broide DH. Familial cold autoinflammatory syndrome: phenotype and genotype of an autosomal dominant periodic fever. J Allergy Clin Immunol 2001;108:615-20
   PubMed Web of Science ®Google Scholar
• Prieur AM, Griscelli C, Lampert F, et al. A chronic, infantile, neurological, cutaneous and articular (CINCA) syndrome. A specific entity analysed in 30 patients. Scand J Rheumatol Suppl 1987;66:57-68
   PubMedGoogle Scholar
• Henderson C, Goldbach-Mansky R. Monogenic IL-1 mediated autoinflammatory and immunodeficiency syndromes: finding the right balance in response to danger signals. Clin Immunol (Orlando, Fla.) 2010;135:210-22
   PubMed Web of Science ®Google Scholar
• Janssen R, Verhard E, Lankester A, et al. Enhanced interleukin-1beta and interleukin-18 release in a patient with chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum 2004;50:3329-33
   PubMed Web of Science ®Google Scholar
• Maksimovic L, Stirnemann J, Caux F, et al. New CIAS1 mutation and anakinra efficacy in overlapping of Muckle-Wells and familial cold autoinflammatory syndromes. Rheumatology (Oxford, England) 2008;47:309-10
   PubMed Web of Science ®Google Scholar
• Bilginer Y, Akpolat T, Ozen S. Renal amyloidosis in children. Pediatr Nephrol (Berlin, Germany) 2011;26:1215-27
   PubMed Web of Science ®Google Scholar
• Tran TA, Kone-Paut I, Marie I, et al. Muckle-Wells syndrome and male hypofertility: a case series. Semin Arthritis Rheum 2012;42:327-31
   PubMed Web of Science ®Google Scholar
• Aksentijevich I, D Putnam C, Remmers EF, et al. The clinical continuum of cryopyrinopathies: novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum 2007;56:1273-85
   PubMed Web of Science ®Google Scholar
• Milhavet F, Cuisset L, Hoffman HM, et al. The Infevers autoinflammatory mutation online registry: update with new genes and functions. Hum Mutat 2008;29:803-8
   PubMed Web of Science ®Google Scholar
• Touitou I, Lesage S, McDermott M, et al. Infevers: an evolving mutation database for auto-inflammatory syndromes. Hum Mutat 2004;24:194-8
   PubMed Web of Science ®Google Scholar
• Jeru I, Marlin S, Le Borgne G, et al. Functional consequences of a germline mutation in the leucine-rich repeat domain of NLRP3 identified in an atypical autoinflammatory disorder. Arthritis Rheum 2010;62:1176-85
   PubMedGoogle Scholar
• Jesus AA, Silva CA, Segundo GR, et al. Phenotype-genotype analysis of cryopyrin-associated periodic syndromes (CAPS): description of a rare non-exon 3 and a novel CIAS1 missense mutation. J Clin Immunol 2008;28:134-8
   Google Scholar
• Tanaka N, Izawa K, Saito MK, et al. High incidence of NLRP3 somatic mosaicism in patients with chronic infantile neurologic, cutaneous, articular syndrome: results of an International Multicenter Collaborative Study. Arthritis Rheum 2011;63:3625-32
   PubMed Web of Science ®Google Scholar
• French FMF Consortium. A candidate gene for familial Mediterranean fever. Nat Genet 1997;17:25-31
   PubMed Web of Science ®Google Scholar
• Ancient missense mutations in a new member of the RoRet gene family are likely to cause familial Mediterranean fever. The International FMF Consortium. Cell 1997;90:797-807
   PubMed Web of Science ®Google Scholar
• Dowds TA, Masumoto J, Chen FF, et al. Regulation of cryopyrin/Pypaf1 signaling by pyrin, the familial Mediterranean fever gene product. Biochem Biophys Res Commun 2003;302:575-80
   PubMed Web of Science ®Google Scholar
• Richards N, Schaner P, Diaz A, et al. Interaction between pyrin and the apoptotic speck protein (ASC) modulates ASC-induced apoptosis. J Biol Chem 2001;276:39320-9
   PubMed Web of Science ®Google Scholar
• Hoffman HM, Mueller JL, Broide DH, et al. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 2001;29:301-5
   PubMed Web of Science ®Google Scholar
• Aksentijevich I, Nowak M, Mallah M, et al. De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. Arthritis Rheum 2002;46:3340-8
   PubMed Web of Science ®Google Scholar
• Feldmann J, Prieur AM, Quartier P, et al. Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. Am J Hum Genet 2002;71:198-203
   PubMed Web of Science ®Google Scholar
• Bertin J, DiStefano PS. The PYRIN domain: a novel motif found in apoptosis and inflammation proteins. Cell Death Differ 2000;7:1273-4
   Google Scholar
• Hoffman HM, Rosengren S, Boyle DL, et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 2004;364:1779-85
   PubMed Web of Science ®Google Scholar
• Agostini L, Martinon F, Burns K, et al. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004;20:319-25
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996;87:2095-147
   PubMed Web of Science ®Google Scholar
• Luheshi GN. Cytokines and fever. Mechanisms and sites of action. Ann N Y Acad Sci 1998;856:83-9
   PubMed Web of Science ®Google Scholar
• Hawkins PN, Lachmann HJ, McDermott MF. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med 2003;348:2583-4
   PubMed Web of Science ®Google Scholar
• Ter Haar N, Lachmann H, Ozen S, et al. Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis 2013;72:678-85
   PubMed Web of Science ®Google Scholar
• Ormerod AD, Smart L, Reid TM, Milford-Ward A. Familial cold urticaria. Investigation of a family and response to stanozolol. Arch Dermatol 1993;129:343-6
   Google Scholar
• Vlagopoulos T, Townley R, Villacorte G. Familial cold urticaria. Ann Allergy 1975;34:366-9
   PubMedGoogle Scholar
• Zip CM, Ross JB, Greaves MW, et al. Familial cold urticaria. Clin Exp Dermatol 1993;18:338-41
   Google Scholar
• Gillmore JD, Lovat LB, Persey MR, et al. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet 2001;358:24-9
   PubMed Web of Science ®Google Scholar
• Neven B, Marvillet I, Terrada C, et al. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum 2010;62:258-67
   PubMed Web of Science ®Google Scholar
• Goldbach-Mansky R, Dailey NJ, Canna SW, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. N Engl J Med 2006;355:581-92
   PubMed Web of Science ®Google Scholar
• Kuemmerle-Deschner JB, Lohse P, Koetter I, et al. NLRP3 E311K mutation in a large family with Muckle-Wells syndrome–description of a heterogeneous phenotype and response to treatment. Arthritis Res Ther 2011;13:R196
   PubMed Web of Science ®Google Scholar
• Lepore L, Paloni G, Caorsi R, et al. Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with Anakinra. J Pediatr 2010;157:310-15; e311
   PubMed Web of Science ®Google Scholar
• Leslie KS, Lachmann HJ, Bruning E, et al. Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Arch Dermatol 2006;142:1591-7
   PubMed Web of Science ®Google Scholar
• Ross JB, Finlayson LA, Klotz PJ, et al. Use of anakinra (Kineret) in the treatment of familial cold autoinflammatory syndrome with a 16-month follow-up. J Cutan Med Surg 2008;12:8-16
   PubMed Web of Science ®Google Scholar
• Sibley CH, Plass N, Snow J, et al. Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes. Arthritis Rheum 2012;64:2375-86
   PubMed Web of Science ®Google Scholar
• Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009;360:2416-25
   PubMed Web of Science ®Google Scholar
• Kuemmerle-Deschner JB, Hachulla E, Cartwright R, et al. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis 2011;70:2095-102
   PubMed Web of Science ®Google Scholar
• Imagawa T, Nishikomori R, Takada H, et al. Safety and efficacy of canakinumab in Japanese patients with phenotypes of cryopyrin-associated periodic syndrome as established in the first open-label, phase-3 pivotal study (24-week results). Clin Exp Rheumatol 2013;31:302-9
   PubMed Web of Science ®Google Scholar
• Caorsi R, Lepore L, Zulian F, et al. The schedule of administration of canakinumab in cryopyrin associated periodic syndrome is driven by the phenotype severity rather than the age. Arthritis Res Ther 2013;15:R33
   PubMed Web of Science ®Google Scholar
• Stych B, Dobrovolny D. Familial cold auto-inflammatory syndrome (FCAS): characterization of symptomatology and impact on patients' lives. Curr Med Res Opin 2008;24:1577-82
   PubMed Web of Science ®Google Scholar
• Koné-Paut I, Lachmann HJ, Kuemmerle-Deschner JB, et al. Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study. Arthritis Res Ther 2011;13:R202
   PubMed Web of Science ®Google Scholar
• Goldbach-Mansky R, Shroff SD, Wilson M, et al. A pilot study to evaluate the safety and efficacy of the long-acting interleukin-1 inhibitor rilonacept (interleukin-1 Trap) in patients with familial cold autoinflammatory syndrome. Arthritis Rheum 2008;58:2432-42
   PubMed Web of Science ®Google Scholar
• Hoffman HM, Throne ML, Amar NJ, et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 2008;58:2443-52
   PubMed Web of Science ®Google Scholar
• Wannamaker W, Davies R, Namchuk M, et al. (S)-1-((S)-2-{1-(4-amino-3-chloro-phenyl)-methanoyl]-amino}-3,3-dimethyl-butanoy l)-pyrrolidine-2-carboxylic acid ((2R,3S)-2-ethoxy-5-oxo-tetrahydro-furan-3-yl)-amide (VX-765), an orally available selective interleukin (IL)-converting enzyme/caspase-1 inhibitor, exhibits potent anti-inflammatory activities by inhibiting the release of IL-1beta and IL-18. J Pharmacol Exp Ther 2007;321:509-16
   PubMed Web of Science ®Google Scholar
• Stack JH, Beaumont K, Larsen PD, et al. IL-converting enzyme/caspase-1 inhibitor VX-765 blocks the hypersensitive response to an inflammatory stimulus in monocytes from familial cold autoinflammatory syndrome patients. J Immunol (Baltimore, Md 1950) 2005;175:2630-4
   PubMed Web of Science ®Google Scholar
• Yu JR, Leslie KS. Cryopyrin-associated periodic syndrome: an update on diagnosis and treatment response. Curr Allergy Asthma Rep 2011;11:12-20
   PubMed Web of Science ®Google Scholar